Synonym
Quinisocaine; Dimethisoquin; Histaderme; Pruralgin; Pruralgan; Chinisocain; Prulantex; Quinisocain; Quinoleine; Kinisocaine; NSC-39695; NSC39695; NSC 39695;
IUPAC/Chemical Name
2-((3-butylisoquinolin-1-yl)oxy)-N,N-dimethylethan-1-amine
InChi Key
XNMYNYSCEJBRPZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H24N2O/c1-4-5-9-15-13-14-8-6-7-10-16(14)17(18-15)20-12-11-19(2)3/h6-8,10,13H,4-5,9,11-12H2,1-3H3
SMILES Code
CCCCC1=CC2=C(C(OCCN(C)C)=N1)C=CC=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
272.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Jayaram V, Sridhar T, Sharma GVM, Berrée F, Carboni B. Synthesis of Polysubstituted Isoquinolines and Related Fused Pyridines from Alkenyl Boronic Esters via a Copper-Catalyzed Azidation/Aza-Wittig Condensation Sequence. J Org Chem. 2018 Jan 19;83(2):843-853. doi: 10.1021/acs.joc.7b02831. Epub 2018 Jan 5. PMID: 29251507.
2: Wang XD, Lin P, Li YX, Chen G, Yang H, He Y, Li Q, Liu RC. Identification of potential agents for thymoma by integrated analyses of differentially expressed tumour-associated genes and molecular docking experiments. Exp Ther Med. 2019 Sep;18(3):2001-2014. doi: 10.3892/etm.2019.7817. Epub 2019 Jul 26. PMID: 31452699; PMCID: PMC6704584.
3: McPartland JM. Travell trigger points--molecular and osteopathic perspectives. J Am Osteopath Assoc. 2004 Jun;104(6):244-9. PMID: 15233331.
4: ROBINSON MM. Use of dimethisoquin in pruritic dermatoses: a three year study. South Med J. 1957 Mar;50(3):367-9. doi: 10.1097/00007611-195703000-00015. PMID: 13409110.
5: GROLNICK M. Case reports; sensitization to quotane and to para-aminobenzoic acid derivatives; report of a case with cross-sensitization reactions. N Y State J Med. 1953 Feb 15;53(4):442-4. English, Undetermined Language. PMID: 13025769.
6: Dunn SM, Blanchard SG, Raftery MA. Effects of local anesthetics and histrionicotoxin on the binding of carbamoylcholine to membrane-bound acetylcholine receptor. Biochemistry. 1981 Sep 15;20(19):5617-24. doi: 10.1021/bi00522a041. PMID: 7295697.
7: Gentry CL, Lukas RJ. Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. J Pharmacol Exp Ther. 2001 Dec;299(3):1038-48. PMID: 11714893.
8: Boyd ND, Cohen JB. Desensitization of membrane-bound Torpedo acetylcholine receptor by amine noncompetitive antagonists and aliphatic alcohols: studies of [3H]acetylcholine binding and 22Na+ ion fluxes. Biochemistry. 1984 Aug 28;23(18):4023-33. doi: 10.1021/bi00313a003. PMID: 6091734.
9: Neubig RR, Cohen JB. Equilibrium binding of [3H]tubocurarine and [3H]acetylcholine by Torpedo postsynaptic membranes: stoichiometry and ligand interactions. Biochemistry. 1979 Nov 27;18(24):5464-75. doi: 10.1021/bi00591a032. PMID: 518850.
10: Nishizawa Y, Gusovsky F, Daly JW. Local anesthetics: stimulation of incorporation of inositol into phosphoinositides in guinea pig cerebral cortical synaptoneurosomes. Biochim Biophys Acta. 1990 Sep 1;1054(2):213-8. doi: 10.1016/0167-4889(90)90243-7. PMID: 2169310.
